CERUS CORP
Customers
3
0 disclosed, 1 federal agency
Suppliers
0
None disclosed
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Federal obligations
$33.2M
FY2026 · USAspending.gov
Latest period
Mar 31, 2016
10-Q filed 2016-05-06
Customers 2
Companies CERS discloses as major customers, as a share of CERS revenue. 0 active, 2 lapsed.
| Company | % of CERS revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| GRFS Grifols SA |
18% | $7.1M | FY 2013-12-31 | Lapsed Last seen 2013-12-31 |
10-K 2016-03-09 | |
Grifols * * 18 % | ||||||
| RFL Rafael Holdings, Inc. |
11% | — | 3M 2016-03-31 | +1.0pp | Lapsed Last seen 2016-03-31 |
10-Q 2016-05-06 |
Medical Device ApS 11 % * Medical Device APS * 10 % * * | ||||||
Federal contracts 1
Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $33.2M in the latest fiscal year shown per agency.
| Agency | Obligated | Fiscal year | Awards | Trend | Largest award |
|---|---|---|---|---|---|
| Department of Health and Human Services
Office of Assistant Secretary for Preparedness and Response |
$33.2M | FY 2026 | 3 | $36.5M → $32.1M → $33.2M | 75A50124C00046 |
LICENSE PATHOGEN REDUCTION TECHNOLOGY (PRT) FOR RED BLOOD CELL (RBC) COMPONENTS TO REDUCE THE RISK OF TRANSFUSION-TRANSMITTED INFECTION (TTI) BY RECOGNIZED, EMERGING, EPIDEMIC, AND ENDEMIC PATHOGENS THAT IS CAPABLE OF TREATING OVER 10 MILLION RBC COM | |||||
Alerts are coming
Get an email when CERS's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.